|Monday, 9 July 2018, 14:07 HKT/SGT|
TOKYO, July 9, 2018 - (JCN Newswire) - Eisai Co., Ltd., Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announce that results from two phase 3 clinical trials (a 2-week double-blind placebo-controlled phase 3 trial and an open-label single-arm 52-week long-term phase 3 trial) for the bile acid transporter inhibitor "GOOFICE 5mg Tablet" (nonproprietary name: elobixibat hydrate; development code: AJG533, hereinafter "elobixibat") have been published in The Lancet Gastroenterology & Hepatology(1)) a journal of The Lancet which is one of the world's most influential medical journals.
The 2-week double-blind clinical trial was a placebo-controlled, randomized, double-blind trial with 133 Japanese patients with chronic constipation. Patients were orally administered 10 mg of elobixibat or placebo once daily for 2 weeks. The elobixibat group demonstrated statistically significant improvements in the primary endpoint of change in spontaneous bowel movement(2) frequency, as well as in secondary endpoints including change in complete spontaneous bowel movement(3) frequency (the secondary endpoint), length of time between dosing and the first spontaneous bowel movement, compared to the placebo group. The major side effects were abdominal pain, diarrhea and other gastrointestinal symptoms. There were no serious side effects.
The 52-week open-label phase 3 clinical trial was a single arm trial to evaluate the efficacy and safety of long-term administration of elobixibat in 341 Japanese patients with chronic constipation. The initial dose was 10 mg once daily orally for 7 days. The dose was increased or decreased in the range of 5, 10 and 15 mg per day appropriately depending on the symptoms and given for 52 weeks. As a result, constipation-related improvements including spontaneous bowel movement frequency, complete spontaneous bowel movement frequency and stool consistency were observed as early as 1 week of administration, and the effects were maintained favorably through 52 weeks. The longer the dosing period, the higher patients' satisfaction relating to defecation tended to be. In addition, in all the JPAC-QOL(4)) scores, there were statistically significant declines(5)) compared to baseline. The major side effects were abdominal pain, diarrhea, lower abdominal pain and other gastrointestinal symptoms. A serious side effect (inguinal hernia) was observed in 1 patient.
The above clinical trial results were presented at Digestive Disease Week (DDW) 2018, June 2-5 in Washington D.C., USA.
Elobixibat was jointly developed by EA Pharma and Mochida. EA Pharma and Mochida distribute elobixibat under the same brand name "GOOFICE 5mg Tablet", respectively, in Japan. EA Pharma and Eisai jointly provide proper use information of "GOOFICE 5mg Tablet" under a co-promotion agreement.
EA Pharma, Eisai and Mochida strive to make a further contribution to improve QOL for patients with chronic constipation through maximization of the product value of "GOOFICE 5mg Tablet".
(1) Atsushi Nakajima et al. "Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial" The Lancet Gastroenterology & Hepatology; 2018; 3: 537-547
(2) Defecation that occurs without a laxative, enema or manual disimpaction
(3) Spontaneous bowel movement without a feeling of incomplete evacuation
(4) Japanese version of the Patient Assessment of Constipation Quality of Life questionnaire(PAC- QOL)
(5) Lower scores mean better quality of life
About elobixibat(Nonproprietary name: elobixibat hydrate; development code AJG533; brand name "GOOFICE 5 mg Tablet")
Elobixibat is a once-daily, orally available chronic constipation* treatment with a novel action mechanism. EA Pharma in-licensed this product from Albireo AB (Headquarters: Sweden) and obtained manufacture and marketing approval in Japan. Elobixibat inhibits the bile acid transporter that regulates reabsorption of bile acids thereby increasing the flow of bile acids to the colon. Elobixibat is the world's first pharmaceutical product approved for marketing with the above action mechanism. The dual action of moisture secretion and bowel movement promotion by bile acids can facilitate defecation.
*Excluding structural disease-caused constipation
About The Lancet Gastroenterology & Herpetology
The Lancet Gastroenterology & Hepatology is a journal of The Lancet journals, focusing on the gastroenterology and hepatology. The Lancet is one of the 5 most-impacting medical journals in the world.
About EA Pharma Co., Ltd.
EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 years' history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma is a gastrointestinal specialty pharma with a full value chain covering R&D, logistics and sales & marketing.
For more information on EA Pharma Co., Ltd., please see http://www.eapharma.co.jp/en/
About Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. has been committed to research and development of innovative pharmaceutical products since its establishment thereby providing distinctive medicines to the medical field. Currently, the core pharmaceutical business focuses resources on the targeted areas of cardiovascular, obstetrics and gynecology, dermatology, psychiatry and gastroenterology, while also providing medicine for intractable disease as well as generics including biosimilars, to meet medical needs.
For more information on Mochida Pharmaceutical Co., Ltd., please see http://www.mochida.co.jp/english/
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit www.eisai.com.
EA Pharma Co., Ltd.
Corporate Planning Dept.
Mochida Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
July 9, 2018 14:07 HKT/SGT
Eisai (TSE: 4523)
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|Sept 5, 2018 14:28 HKT/SGT|
Eisai And Merck & Co. Announce China NMPA Approval of First Approval for LENVIMA (Lenvatinib) for Treatment of Unresectable HCC|
|Sept 3, 2018 14:50 HKT/SGT|
Eisai Receives Approval for Partial Label Change for Vascular Embolization Device DC Bead|
|Aug 30, 2018 09:36 HKT/SGT|
Eisai's LENVIMA (LENVATINIB) Capsules Approved for First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC) in South Korea|
|Aug 29, 2018 10:25 HKT/SGT|
Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab|
|Aug 28, 2018 09:11 HKT/SGT|
Eisai: Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ |
|Aug 23, 2018 08:00 HKT/SGT|
Eisai: European Commission Grants Marketing Authorization for LENVIMA (Lenvatinib) |
|July 31, 2018 14:13 HKT/SGT|
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in China to CY Biotech|
|July 31, 2018 10:27 HKT/SGT|
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA|
|July 26, 2018 10:34 HKT/SGT|
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at AAIC 2018|
|July 26, 2018 08:01 HKT/SGT|
Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018|
|More news >>|